治疗系统性红斑狼的巴里西替尼:双盲,随机,安慰剂对照的第三阶段试验 (SLE- BRAVE- I)
Eric F Morand1, Edward M Vital2, Michelle Petri3
1Centre for Inflammatory Disease, Monash University, Melbourne, VIC, Australia; School of Clinical Sciences, Monash University Clayton, Melbourne, VIC, Australia.
Lancet (London, England)
|February 27, 2023
概括
在一项为期52周的研究中,巴里西替尼4mg显著改善了全身性红斑狼 (SLE) 疾病的活性,达到主要终点. 然而,二次终点没有达到,安全性概况与已知的数据一致.
科学领域:
- 免疫学
- 关节病学
- 药理学
背景情况:
- 巴里西替尼是一种Janus激酶1和2抑制剂,已被批准用于类风湿性关节炎,皮炎和白发性脱发症.
- 之前的一项为期24周的研究表明,巴里西替尼4毫克可以改善系统性红斑狼 (SLE) 患者的疾病活性.
研究的目的:
- 在3期试验中评估巴里西提尼的有效性和安全性.
主要方法:
- 一项多中心,双盲,随机,安慰剂控制的研究 (SLE- BRAVE- I) 分派了760名活跃SLE患者接受4毫克,2毫克或安慰剂治疗.
- 主要终点是患者在第52周达到SLE响应指数 (SRI) - 4响应的比例.
主要成果:
- 与安慰剂相比,巴里西替尼4毫克的SRI-4反应率显著增加 (57%; p=0. 016).
- 与安慰剂相比,巴里西替尼2mg对SRI-4反应没有显著差异 (50%).
- 对于主要的二次终点,包括糖皮质激素的逐渐减少和严重爆发的时间,没有观察到群体之间的显著差异.
结论:
- 在患有SLE的患者中,巴里西替尼4mg达到其主要疗效终点.
- 没有满足关键次要终点,也没有发现新的安全问题.
相关概念视频
Clinical Trials
6.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.9K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
204
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
204
Clinical Trials: Overview
3.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.1K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
226
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
226
Drugs for Treatment of Ulcerative Colitis in IBD
208
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
208


